Suzhou Callisyn Biomedical

Suzhou Callisyn Biomedical is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule drugs for oncology and immune-related disorders. The company was founded by Dr. Wei-Ping Deng, a co-founder of Calistoga Pharmaceuticals and a pioneer in the development of PI3K inhibitors. Callisyn leverages its deep expertise in the PI3K/AKT/mTOR signaling pathway to create a pipeline of next-generation targeted therapies, including dual PI3K/mTOR inhibitors and AXL inhibitors. By focusing on structure-based drug design and translational medicine, the company aims to address unmet medical needs in solid tumors and hematological malignancies. Callisyn is backed by prominent Chinese venture capital firms and operates within the vibrant biotech ecosystem of the Suzhou Industrial Park.